Hemoderivative Market Share Driven by Expanding Therapeutic Use and Biopharma Demand for Plasma-Derived Proteins | Valuates Reports

Hemoderivative Market Size
The global market for Hemoderivative was valued at US$ 9375 million in the year 2024 and is projected to reach a revised size of US$ 14340 million by 2031, growing at a CAGR of 6.5% during the forecast period.

View sample report
https://reports.valuates.com/request/sample/QYRE-Auto-15C19447/Global_Hemoderivative_Market_Research_Report_2025

The Hemoderivative Market is witnessing significant growth, fueled by increasing clinical applications of plasma-derived proteins in chronic disease management, surgical recovery, and immunotherapy. As biologics gain momentum in healthcare, hemoderivatives play a central role in both treatment and formulation.

By type, the Albumin segment holds the largest market share due to its widespread use in volume replacement therapies, liver cirrhosis management, and drug delivery systems. Immunoglobulins follow closely, supported by rising demand for IVIG in immunodeficiency disorders and autoimmune treatments. The Coagulation Factors segment is expanding steadily with the growing need for hemophilia care and surgical bleeding control. The Others category, including fibrinogen and protease inhibitors, is gaining traction in niche and investigational applications.

By application, the Therapeutics segment dominates the market, driven by a growing patient base across immunology, hematology, and critical care. The Excipient segment is also notable, as albumin and other derivatives are increasingly used in biopharmaceutical formulation and vaccine stabilization. Other applications, such as diagnostics and cell culture media, contribute to diversified downstream opportunities.

With global plasma collection infrastructure expanding and regulatory pathways becoming more favorable for biologics, the Hemoderivative Market is positioned for sustained and clinically driven growth.

Segment by Type
• Albumin
• Immunoglobulins
• Coagulation Factors
• Others

Segment by Application

• Therapeutics
• Excipient
• Other

By Company

Grifols, CSL, Takeda, Octapharma, CBPO, Hualan Bio, Kedrion, Shanghai RAAS, LFB Group, Weiguang Bio, Tiantan Bio, Shuanglin Bio, Boya Bio, Yuanda Shuyang

View full report
https://reports.valuates.com/market-reports/QYRE-Auto-15C19447/global-hemoderivative

Valuates,
4th Floor,
Balaraj's Arcade,
Whitefield Main road,
Bangalore 560066,

Valuates offers an extensive collection of market research reports that helps companies to take intelligent strategical decisions based on current and forecasted Market trends.

This release was published on openPR.